USREF dividend yield: 4.00%. ABBV dividend yield: 3.67%. USREF is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in USREF shares. AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.
USREF is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in USREF shares.
AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.
Is USREF or ABBV better for dividend income in 2026?
USREF currently offers a 4.00% yield (2.00/share/year) while ABBV offers 3.67% (6.20/share/year). USREF provides higher current income. However, ABBV has grown its dividend faster (8.9% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in USREF vs ABBV earn per year?
With $10,000 invested today: USREF pays approximately $400/year. ABBV pays approximately $367/year. With DRIP reinvestment over 10 years, these grow to $899/year (USREF) and $1,154/year (ABBV).
Does USREF or ABBV pay monthly dividends?
USREF pays quarterly dividends. ABBV pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this USREF vs ABBV comparison by email
Save your analysis + get weekly dividend insights. Free forever.